Reply to thread

Message: <blockquote data-quote="imhotep" data-source="post: 29730430" data-attributes="member: 562115">There are several non-vaccine mRNA drug candidates in development & testing phases.mRNA-3927 as described here targets a rare genetic disorder, propionic acidemia, in which patients cannot process certain parts of proteins and lipids properly.BNT-141 by BioNTech, targeting ovarian cancer, bile duct cancer, adenocarcinoma of the gastroesophageal junction, colorectal cancer, pancreatic cancer, gastric cancer, solid tumours;LUNARGSD3/UX053 by Ultragenyx, targeting glycogen storage disorder type III, also known as Cori’s Disease;mRNA-3705, Moderna’s second candidate, for methylmalonic acidemia;OTX-2002 by Omega Therapeutics for hepatocellular carcinoma and solid tumours.OTX-2002 is projected to have the highest revenue by 2028, regenerating $1.6bn that year. The sales of all five candidates are forecast to reach over $2bn by 2028.These are major advances in mRNA technology. mRNA was invented in the 1960s, and by the 1970s the scientists knew how to deliver mRNA to a cell.The first mRNA flu vaccine was tested on mice in the 1990s. The first mRNA antirabies vaccine was tested on humans in 2013. The mRNA Ebola vaccine was selectively tested in Africa.Finally it's the Wuhan virus that really kicked the mRNA devlopment to the current state.(I had written before on the mRNA development in the Covid Megathreads)In simple terms mRNA can teach the body how to make a specific protein that helps your immune system to prevent or treat disease conditions.</blockquote>

Verification: Awruddata maasa keeyada?

Top Bottom